William K. Oh

William Oh is a nationally recognized leader in the medical oncology of genitourinary cancers, serving as Chief of Hematology and Medical Oncology at the Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. With more than two decades of experience leading academic clinical trial programs, he has been a principal or co-investigator on studies of virtually every major agent approved for prostate cancer in the modern era, including docetaxel, cabazitaxel, abiraterone, enzalutamide, radium-223, and PARP inhibitors. Oh's clinical and translational research has focused on two interconnected areas: the treatment of castration-resistant prostate cancer and the management of bone metastasis. His laboratory contributed to understanding the mechanisms by which prostate cancer cells colonize bone and remodel the bone microenvironment, including the role of osteoblastic and osteolytic signaling in establishing metastatic lesions. He has led studies of bone-targeting agents including zoledronic acid and denosumab in prostate cancer, and has helped establish consensus on the use of these agents to prevent skeletal-related events. His work on radium-223 in bone-metastatic CRPC contributed to understanding both its mechanism and its sequencing with other life-prolonging agents. Beyond direct therapeutics, Oh has been a leader in population-level prostate cancer research, using large-scale database analyses to characterize treatment patterns, outcomes disparities, and the real-world impact of guideline-concordant care. He has been particularly interested in racial disparities in prostate cancer outcomes, contributing data showing that African American men with prostate cancer have worse outcomes that are partly explained by differences in treatment access and adherence. This work has informed both advocacy efforts and institutional quality improvement programs.

William Oh 是泌尿生殖系统癌症内科治疗领域的全国知名领导者，担任西奈山医学院蒂施癌症研究所血液与内科肿瘤学部主任。他的临床和转化研究集中于两个相互关联的领域：去势抵抗性前列腺癌的治疗和骨转移管理。 Oh 的实验室对前列腺癌细胞骨定植机制做出了贡献，并主导了骨靶向药物的研究。此外，他还通过大规模数据库分析，研究了前列腺癌治疗模式、预后差异和种族不平等问题，为倡导工作和机构质量改进提供了数据支撑。